In solid tumors the main target of these drugs are oncoproteins crucial for tumor maintenance and survival such as epidermal growth factor (EGFR), B-Raf proto-oncogene/serine/threonine kinase (BRAF), proto-oncogene c-Kit (KIT), human epidermal growth factor receptor 2 (HER2) [3,5]. This evidence concerns the gene ERBB2 and neoplasm.